CSIMarket Company Name, Ticker, Competitors, else..
 
Structure Therapeutics Inc   (NASDAQ: GPCR)
 
Price: $38.7200 $-0.83 -2.099%
Day's High: $40.27000045776367 Week Perf: -18.21 %
Day's Low: $ 38.22 30 Day Perf: -28.18 %
Volume (M): 253,686 52 Wk High: $ 94.90
Volume (M$): $ 0 52 Wk Avg: $49.43
Open: $39.82 52 Wk Low: $20.04



 Market Capitalization (Millions $) 8,439
 Shares Outstanding (Millions) 218
 Employees 220
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -215
 Cash Flow (TTM) (Millions $) 164
 Capital Exp. (TTM) (Millions $) 5

Business Description


Structure Therapeutics Inc is a biotechnology company focused on discovering and developing small molecule drugs to target RNA structures implicated in various diseases. The company's research and development efforts are centered around the understanding of RNA structure and how it relates to disease pathways. By targeting specific RNA structures, Structure Therapeutics aims to develop innovative therapies that can effectively regulate gene expression and treat diseases such as cancer, genetic disorders, and viral infections. The company utilizes a combination of computational tools, high-throughput screening, and medicinal chemistry to identify and optimize small molecules that can modulate these RNA structures. Structure Therapeutics aims to provide novel therapeutic options that can address unmet medical needs and improve patient outcomes.


   Company Address: 601 Gateway Blvd. South San Francisco 94080 CA
   Company Phone Number: 457-1978   Stock Exchange / Ticker: NASDAQ GPCR


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
JNJ   -3.42%    
MRK   -5.04%    
PFE   -4.46%    
TEVA   -1.47%    
VRTX   -8.07%    
VTRS   -2.95%    
• View Complete Report
   



Clinical Study

Evaluating the Therapeutic Progression of Structure Therapeutics ACCG-2671s Promising Profile and Financial Insights

Published Sun, Dec 29 2024 10:19 AM UTC

The effective management of obesity remains a daunting challenge in pharmacotherapy, amidst rising prevalence rates and associated comorbidities. Structure Therapeutics Inc. has recently advanced its developmental pipeline with the announcement of its lead oral small molecule amylin receptor agonist, ACCG-2671, targeting the treatment of obesity. This article elucidates the ...
Clinical Study

Advancements in Obesity Management Phase 2b ACCESS Study for GSBR-1290 Demonstrates Promising Potential

Published Wed, Nov 13 2024 9:01 PM UTC

The rising prevalence of obesity has necessitated the development of effective pharmacological interventions. Structure Therapeutics oral small molecule GLP-1 receptor agonist, GSBR-1290, is currently under investigation in the Phase 2b ACCESS clinical study aimed at evaluating its efficacy and safety over a 36-week period. Preliminary results from earlier Phase 2a studies...
Product Service News

Structure Therapeutics Inc. Announces Key Leadership Changes to Propel Development of Novel Therapeutics

Published Tue, Sep 17 2024 8:05 PM UTC

: Structure Therapeutics Inc. a clinical-stage global biopharmaceutical firm focused on developing innovative oral small molecule therapeutics for metabolic and cardiopulmonary diseases, has announced significant leadership changes aimed at enhancing operational efficiency and advancing its drug development programs. On September 17, 2024, Structure Therapeutics Inc. (NASD...
Financing Agreement

Structure Therapeutics Inc. Raises $547.4 Million in Public Offering, Faces Quick Ratio Challenges

Published Fri, Jun 7 2024 8:05 PM UTC

Structure Therapeutics Inc. recently announced the successful closing of its upsized underwritten public offering, which saw the sale of 10,427,017 American depositary shares (ADSs) at a price of $52.50 per ADS. This resulted in aggregate gross proceeds of approximately $547.4 million for the company.
However, despite a sequential decrease in current liabilities, the co...
Stock Market Announcement

Structure Therapeutics Announces Successful Pricing of Upsized $476 Million Public Offering amidst Encouraging Market Performance

Published Wed, Jun 5 2024 11:54 PM UTC



San Francisco-based biopharmaceutical company, Structure Therapeutics Inc., recently unveiled the pricing details of its upsized underwritten public offering. The offering, comprising 9,066,972 American depositary shares (ADSs) at a price of $52.50 per ADS, is predicted to generate approximately $476.0 million in gross proceeds for the company. Furthermore, an opti...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 6.23
PEG (TTM) -

Financial Strength Current
Quick Ratio 20.31
Working Capital Ratio 20.75
Leverage Ratio (MRQ) 0.05
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.02 $
Revenues (TTM) -
Cash Flow (TTM) 0.75 $
Cash 6.16 $
Book Value 6.21 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -976,523
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.